Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YM155 plus rituximab in previously treated CD20-positive B-cell non-Hodgkin lymphoma
2009-010777-20Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Oct 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sepantronium and rituximab in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL) and 1 more, sponsored by Astellas Pharma. Primary endpoint: Objective response rate. Started Oct 2009; status: completed.
02
Drugs
sepantroniumrituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)mantle cell lymphoma (MCL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on 2009-010777-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010777-20.